Since 1970, a committee of experts in the field of primary immunodeficiencies (PIDs) has met every 2 years with the goal of classifying and defining these disorders. The most recent meeting, organized by the Experts Committee on Primary Immunodeficiencies of the International Union of Immunological Societies, with support from the Jeffrey Modell Foundation and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, took place in Dublin, Ireland, in June 2009. In addition to members of the expert committee, the meeting gathered more than 30 speakers and more than 200 participants from 6 continents. Recent discoveries on the molecular and cellular bases of PID and advances in the diagnosis and treatment of these disorders were discussed. At the end of the meeting, the International Union of Immunological Societies Expert Committee on Primary Immunodeficiencies met to update the classification of PIDs, presented in Tables I to VIII. The general outline of the classification has remained substantially unchanged. Novel PIDs, whose molecular basis has been identified and reported in the last 2 years, have been added to the list. In Table I (Combined T and B-cell immunodeficiencies), coronin-1A deficiency (resulting in impaired thymic egress) has been added to the genetic defects causing T -B 1 severe combined immunodeficiency (SCID). The first case of DNA-activated Protein Kinase catalytic subunit (DNA-PKcs) deficiency has also been reported and adds to the list of defects of nonhomologous end-joining resulting in T -B -SCID. Among calcium flux defects, defects of Stromal Interaction Molecule 1 (STIM-1), a Ca 11 sensor, have been reported in children with immunodeficiency, myopathy, and autoimmunity. Mutations of the gene encoding the dedicator of cytokinesis 8 protein have been shown to cause an autosomal-recessive combined immunodeficiency with hyper-IgE, also characterized by extensive cutaneous viral infections, severe atopy, and increased risk of cancer. Also in Table I , mutations of the adenylate kinase 2 gene have been shown to cause reticular dysgenesis, and mutations in DNA ligase IV (LIG4), adenosine deaminase (ADA), and gc have been added to the list of genetic defects that may cause Omenn syndrome.
In Table II (Predominantly antibody deficiencies), mutations in Transmembrane Activator and CAML Interactor (TACI) and in B cell activating factor (BAFF)-receptor have been added to the list of gene defects that may cause hypogammaglobulinemia. However, it should be noted that only few TACI mutations appear to be disease-causing. Furthermore, variability of clinical expression has been associated with the rare BAFF-receptor deficiency. Table  III lists other well defined immunodeficiency syndromes. PostMeiotic Segregation 2 (PMS2) deficiency and immunodeficiency with centromeric instability and facial anomalies syndrome have been added to the list of DNA repair defects, whereas ComelNetherton syndrome is now included among the immune-osseous dysplasias, and hyper-IgE syndrome caused by dedicator of cytokinesis 8 (DOCK8) mutation has also been added. Interleukin-2 Inducible T cell Kinase (ITK) deficiency has been included among the molecular causes of lymphoproliferative syndrome in Table IV (Diseases of immune dysregulation). Also in Table  IV , CD25 deficiency has been listed to reflect the occurrence of autoimmunity in this rare disorder. Progress in the molecular characterization of congenital neutropenia and other innate immunity defects has resulted in the inclusion of Glucose-6-phosphate Transporter 1 (G6PT1) and Glucose-6-phosphate catalytic subunit 3 (G6PC3) defects in Table V (Congenital defects of phagocyte number, function, or both) and of MyD88 deficiency (causing recurrent pyogenic bacterial infections) and of CARD9 deficiency (causing chronic mucocutaneous candidiasis) in Table  VI (Defects in innate immunity). Tables V and VI also include 2 novel genetic defects that result in clinical phenotypes distinct from the classical definition of PIDs. In particular, mutations of the Colony Stimulating Factor 2 Receptor Alpha (CSF2RA) gene, encoding for GM-CSF receptor a, have been shown to cause primary alveolar proteinosis as a result of defective surfactant catabolism by alveolar macrophages (Table V) . Mutations in Apoliprotein L 1 (APOL1) are associated with trypanosomiasis, as reported in Table VI . It can be anticipated that a growing number of defects in immune-related genes will be shown to be responsible for nonclassic forms of PIDs in the future. Along the same line, the spectrum of genetically defined autoinflammatory disorders (Table VII) has expanded to include NLR family pyrin domain-containing 12 (NLRP12) mutations (responsible for familial cold autoinflammatory syndrome) and Interleukin-1 receptor antagonist (IL1RN) defects (causing deficiency of the IL-1 receptor antagonist). Again, it is expected that a growing number of genetic defects will be identified in other inflammatory conditions. Finally, defects of ficolin 3 (which plays an important role in complement activation) have been shown to cause recurrent pyogenic infections in the lung (Table VIII) .
Although the revised classification of PIDs is meant to assist with the identification, diagnosis, and treatment of patients with these conditions, it should not be used dogmatically. In particular, although the typical clinical and immunologic phenotype is reported for each PID, it has been increasingly recognized that the phenotypic spectrum of these disorders is wider than originally thought. This variability reflects both the effect of different mutations within PID-causing genes and the role of other genetic, epigenetic, and environmental factors in modifying the phenotype. For example, germline hypomorphic mutations or somatic mutations in SCID-related genes may result in atypical/leaky SCID or Omenn syndrome, with the latter associated with significant immunopathology. Furthermore, infections may also significantly modify the clinical and immunologic phenotype, even in patients who initially present with typical SCID. Thus, the phenotype associated with single-gene defects listed in the revised classification should by no means be considered absolute.
Finally, a new column has been added to the revised classification to illustrate the relative frequency of the various PID disorders. It should be noted that these frequency estimates are based on what has been reported in the literature because with few exceptions, no solid epidemiologic data exist that can be reliably used to define the incidence of PID disorders. Furthermore, the frequency of PIDs may vary in different countries. Certain populations (and especially, some restricted ethnic groups of geographical isolates) have a higher frequency of specific PID mutations because of a founder effect and genetic drift. For example, DNA cross-link repair protein 1C (DCLRE1C) (Artemis) and Z-associated protein of 70 kD (ZAP70) defects are significantly more common in Athabascan-speaking Native Americans and in members of the Mennonite Church, respectively, than in other populations. Similarly, MHC class II deficiency is more frequent in Northern Africa. The frequency of autosomal-recessive immunodeficiencies is higher among populations with a high consanguinity rate. AD, Autosomal-dominant; AIRE, autoimmune regulator; AP3B1, adaptor protein complex 3 beta 1 subunit; AR, autosomal-recessive; CASP, caspase; CTL, cytotoxic T lymphocyte; DN, double-negative; FOXP3, forkhead box protein 3; LYST, lysosomal trafficking regulator; NRAS, neuroblastoma Ras protein; PRF1, perforin 1; RAB27A, Ras-associated protein 27A; SH2D1A, SH2 domain protein 1A; TNFRSF6, tumor Necrosis Factor Receptor Soluble Factor 6; TNFSF6, tumor Necrosis Factor Soluble Factor 6; IAP, X-linked inhibitor of apoptosis; XL, X-linked; XLP, X-linked lymphoproliferative disease ACTB, Actin beta; AD, autosomal-dominant; AR, autosomal-recessive inheritance; CEBPE, CCAAT/Enhancer-binding protein epsilon; CTSC, cathepsin C; CYBA, cytochrome b alpha subunit; CYBB, cytochrome b beta subunit; ELA2, elastase 2; IFN, interferon; IFNGR1, interferon-gamma receptor subunit 1; IFNGR2, interferon-gamma receptor subunit 2; L12B, interleukin-12 beta subunit; IL12RB1, interleukin-12 receptor beta 1; F, fibroblasts; FPR1, formylpeptide receptor 1; FUCT1, fucose transporter 1; GFI1, growth factor independent 1; HAX1, HLCS1-associated protein X1; ITGB2, integrin beta-2; L, lymphocytes; M, monocytes-macrophages; MAPBPIP, MAPBP-interacting protein; Mel, melanocytes; N, neutrophils; NCF1, neutrophil cytosolic factor 1; NCF2, neutrophil cytosolic factor 2; NK, natural killer cells; SBDS, Shwachman-Bodian-Diamond syndrome; STAT, signal transducer and activator of transcription; XL, X-linked inheritance. *Cognitive and neurologic defects are observed in a fraction of patients. Periodontitis may be isolated. IKBA, inhibitor of NF-kB alpha; IRAK4, interleukin-1 receptor associated kinase 4; MYD88, myeloid differentiation primary response gene 88; NEMO, NF-kB essential modulator; NF-kB, nuclear factor-kB; SDF-1, stromal-derived factor 1; TIR, toll and IL-1 receptor; TLR, toll-like receptor; XL, X-linked. *Only a few patients have been genetically investigated, and they represented a small fraction of all patients tested, but the clinical phenotype being common, these genetic disorders may actually be more common. **Mutations in CARD9 have been identified only in one family. Other cases of chronic mucocutaneous candidiasis remain genetically undefined. AD, Autosomal dominant inheritance; AR, autosomal-recessive inheritance; ASC, apoptosis-associated specklike protein with a caspase recruitment domain; CARD, caspase recruitment domain; CD2BP1, CD2 binding protein 1; CIAS1, cold-induced autoinflammatory syndrome 1; LPN2, lipin-2; MEFV, Mediterranean fever; MVK, mevalonate kinase; NF-kB, nuclear factor-kB; PMN, polymorphonuclear cell; PSTPIP1, proline/serine/threonine phosphatase-interacting protein 1; SNHL, sensorineural hearing loss. *All 3 syndromes associated with similar CIAS1 mutations; disease phenotype in any individual appears to depend on modifying effects of other genes and environmental factors. 
